ERX-315 introduced at SABCS 2023

San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…

Independent validation of LIPA as a molecular target in TNBC

Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany. The authors conclude that LIPA-activity is a novel…

One year later, highest almetric score for any paper published in Nature Cancer!

 Dallas, Texas. June 1, 2023:   One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…

Positive preclinical data presented at AACR 2023

 Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award

Dallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…

Etira founder Dr. Jung-Mo Ahn highlighted in local press

Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…

Oncology Times Highlights ERX-41

Dallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar…

Etira selected as a 2022 BioNTX rising star

Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star. The BioNTX iC³ Life Science Summit is a two-day conference, held on September 22-23, 2022 that serves as a forum where…

ERX-41 Paper image selected for Nature Cancer cover

Dallas, Texas. July 7, 2022: On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr. Andrew S. Moore, Janelia Research Campus. Cover Design by Allen Beattie. Highlighted…